<DOC>
	<DOCNO>NCT01516229</DOCNO>
	<brief_summary>This study conduct Japan . The aim study assess incidence rate adverse drug reaction ( ADRs ) use somatropin ( NorditropinÂ® ) treatment achondroplasia without epiphyseal line closure normal clinical practice condition .</brief_summary>
	<brief_title>Special Survey Long Term Application</brief_title>
	<detailed_description />
	<mesh_term>Achondroplasia</mesh_term>
	<criteria>Achondroplasia without epiphyseal line closure</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>